Economic outcomes of centralized procurements of gene therapy for patients with orphan diseases: inherited retinal dystrophy
Background. New pathogenetic treatment options, such as gene therapy, are now used to treat previously uncurable diseases. However, price of such treatment is high, especially in the case of orphan diseases, where costs may many-fold exceed the prices for other types of medication. This raises a que...
Saved in:
| Main Authors: | N. А. Avxentyev, Yu. V. Makarova, V. V. Kadyshev |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IRBIS LLC
2022-01-01
|
| Series: | Фармакоэкономика |
| Subjects: | |
| Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/623 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Prospects for the diagnosis and gene therapy of inherited retinal dystrophies caused by biallelic mutations in the RPE65 gene
by: V. V. Neroev, et al.
Published: (2021-09-01) -
First results of long-term follow-up of children in Russia after gene therapy for hereditary retinal dystrophies associated with biallelic mutations in the RPE65 gene
by: V. V. Neroev, et al.
Published: (2023-12-01) -
A decision making algorithm for inherited retinal dystrophies, caused by biallelic mutations in the RPE65 gene, in the clinical practice of an ophthalmologist
by: E. I. Saidasheva, et al.
Published: (2022-03-01) -
Leber’s Congenital Amaurosis and its Complications – A Very Rare Presentation
by: Sujit Das, et al.
Published: (2024-01-01) -
Longitudinal Assessment of Structural and Functional Changes in Rod-cone Dystrophy: A 10-year Follow-up Study
by: Alexis Ceecee Britten-Jones, BOptom (Hons), PhD, et al.
Published: (2025-03-01)